



Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
						AMG-Studien				
Mamma-Ca	x	x			ADAPT EudraCT number: 2011-001462-17	Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Phase III	x			
Mamma-Ca	x				GeparX EudraCT Number 2015-001755-72	Investigating Denosumab as an add-on neoajuvant treatment for hormon receptor negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules;2x2 factorial design	x	x	x	x
Mamma-Ca	x				PH002-TP-II EudraCT Number 2016-005157-21	A prospective, randomized, multicenter, open-label comparison of pre-surgical combination of trastuzumab and pertuzumab with concurrent taxane chemotherapy or endocrine therapy given for twelve weeks with a quality of life assessment of trastuzumab, pertuzumab in combination with standard (neo)adjuvant treatment in patients with operable HER2+/HR+ breast cancer.		x		
Mamma-Ca	x				Impassion050 BO40747 EudraCT Number 2018-001881-40	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN <input type="checkbox"/> CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL <input type="checkbox"/> TRASTUZUMAB <input type="checkbox"/> PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER		x	x	
Mamma-Ca	x				GeparDouze EudraCT Number 2017-002771-25	A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo				x



Mamma-Ca				x	VIOLETTE EudraCT Number 2017-002361-22	A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE)					x
Mamma-Ca				x	Veronica (Venetoclax) WO40181 EudraCT Number 2017-005118-74	A PHASE II, MULTICENTER, RANDOMIZED STUDY TO COMPARE THE EFFICACY OF VENETOCLAX PLUS FULVESTRANT VERSUS FULVESTRANT IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO EXPERIENCED DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER CDK4/6 INHIBITOR THERAPY		x			
Mamma-Ca				x?	SGN-LVA-002 EudraCT Number 2017-002289-35	Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer					x
Indikation	Neo-Adjuvant	first-line	second-line	further lines	Kurztitel	Vollständiger Titel					

						BIO-Marker Studien				
--	--	--	--	--	--	---------------------------	--	--	--	--

						Präventionsstudien				
--	--	--	--	--	--	---------------------------	--	--	--	--

						Sonstige Studien				
--	--	--	--	--	--	-------------------------	--	--	--	--



Mamma-Ca						GATTUM	Prospektive Evaluation der Notwendigkeit einer atemgetriggerten Bestrahlung (gating) beim linksseitigen Mammakarzinom	x	x	x	x
Mamma-Ca						SaveHeart	Prospektive Studie zur Herzschonung durch Bestrahlung in tiefer Inspiration bei linksseitigem Mammakarzinom	x	x	x	x
Mamma- Ca und Schwangerschaft						GBG 29 (German Breast Group)	Prospektive Registerstudie zur Diagnostik und Therapie des Mamma-karzinoms in der Schwangerschaft Pat. mit histologisch gesichertem Mammakarzinom und Schwangerschaft	x	x	x	x
Gyn-Sarkome	x	x	x	x		REGSA	Deutsche prospektive Registerstudie zur Erfassung der				
Mamma-Ca						PATH	Physical Activity during primary Therapy of breast cancer	x	x	x	x
Mamma-Ca beim Mann						Register Magdeburg	Mammakarzinom des Mannes. Eine prospektive Registerstudie der Universitätsfrauenklinik Magdeburg in Zusammenarbeit mit den klinischen Krebsregistern zur Diagnostik und Therapie des Mammakarzinoms des Mannes	x	x	x	x
Kaiserschnitt Babies							Effect, tolerance and safety of a supplementation with a probiotic in health newborn term infants born by Cesarean section over a 12 month period				